Description
Anti-Ebola virus glycoprotein Antibody, Non-Fucosylated (BioBet-1695ZP) is a humanized monoclonal IgG antibody against Ebola virus glycoprotein. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Ebola virus glycoprotein antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Ebola virus glycoprotein
Alternative Names
Ebola virus; EBOV; Ebola virus glycoprotein (GP)
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1695ZP
Description
Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved in vivo by fucosylated counterparts through competition for high levels of ADCC effectiveness of non-fucosylated therapeutic antibody molecules to bind antigen on target cells.
